Revision as of 09:22, 9 January 2024 editMaxim Masiutin (talk | contribs)Extended confirmed users, IP block exemptions, Pending changes reviewers31,055 edits Added bibcode. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.← Previous edit | Latest revision as of 16:18, 21 October 2024 edit undoJWBE (talk | contribs)Extended confirmed users10,127 edits removed Category:Phenols; added Category:Hydroxyarenes using HotCat | ||
Line 60: | Line 60: | ||
] | ] | ||
] | ] | ||
] | ] | ||
] | ] |
Latest revision as of 16:18, 21 October 2024
Chemical compoundPharmaceutical compound
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C18H23NO2 |
Molar mass | 285.387 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(verify) |
Ketazocine (INN), also known as ketocyclazocine, is a benzomorphan derivative used in opioid receptor research. Ketazocine, for which the receptor is named, is an exogenous opioid that binds to the κ opioid receptor.
Activation of this receptor is known to cause sleepiness, a decrease in pain sensation and (potentially) dysphoria, paranoia, and hallucinations. It also causes an increase in urine production because it inhibits the release of vasopressin. (Vasopressin is an endogenous substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)
Unlike other opioids, substances that only bind to the κ receptor theoretically do not depress the respiratory system.
The crystal structure of ketazocine was determined in 1983.
See also
References
- Leander JD (September 1982). "Effects of ketazocine, ethylketazocine and phenazocine on schedule-controlled behavior: antagonism by naloxone". Neuropharmacology. 21 (9): 923–8. doi:10.1016/0028-3908(82)90085-5. PMID 6128693. S2CID 38692038.
- Verlinde CL, De Ranter CJ (1983). "(1S, 5R, 9R)-2-Cyclopropylmethyl-2'-hydroxy-5, 9-dimethyl-8-oxo-6, 7-benzomorphan hydrochloride monohydrate (ketazocine), C18H23NO2. HCl. H2O". Acta Crystallogr. C. 39 (12): 1703–1706. Bibcode:1983AcCrC..39.1703V. doi:10.1107/S0108270183009828.
Opioid receptor modulators | |||||
---|---|---|---|---|---|
μ-opioid (MOR) |
| ||||
δ-opioid (DOR) |
| ||||
κ-opioid (KOR) |
| ||||
Nociceptin (NOP) |
| ||||
Others |
|